TLSI News & Events

TriSalus Life Sciences announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering are to be sold by TriSalus. Lake Street Capital Markets is acting as the sole book-runner for the proposed offering.

TriSalus Life Sciences announced changes to its Board of Directors. TriSalus announced that Dr. Arjun Desai, a member of the Board since August of 2023, has elected to resign from the Board. Concurrently, TriSalus announced that Michael Stansky has been appointed to the Company's Board of Directors, effective February 4, 2026.

"TriSalus continued to deliver strong commercial performance in the fourth quarter and exceeded our 2025 guidance of 50% annual revenue growth, underscoring the meaningful clinical adoption of our TriNav product suite and proprietary PEDD platform across a broad range of solid tumor indications," said Mary Szela, president and CEO of TriSalus. "We are pleased not only with our commercial execution but also with the sustained progress on our strategic initiatives, including expansion of the TriNav platform across multiple indications beyond the liver and deepening our engagement within the interventional radiology community. Looking ahead to 2026, we expect full-year revenues to be in a range of approximately $60 million to $62 million."